Summary
- Main use
- Improvement of glycemic control in type 2 diabetes mellitus
- Who uses it
- Adults
- Adult dosage
- This medicine may be administered as monotherapy or in combination with metformin in patients with no prior experience of antidiabetic drug therapy. The dose is 50mg once daily in the morning, or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione alone, the recommended dose of this medicine when used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea alone, the recommended dose of this medicine when used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose of this medicine as add-on therapy (third-agent therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this medicine when used in combination is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food. Doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. - Moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under ‘3. General precautions’ in Precautions for use.)
Ingredients
- Manufacturer
- Hanmi Pharmaceutical Co., Ltd.
Efficacy & effects
Improvement of glycemic control in type 2 diabetes mellitus
View approved original textHide original text
This medication is used in conjunction with dietary and exercise management to assist in blood sugar control for patients with type 2 diabetes. It can be administered alone or in combination with other agents. This helps effectively improve blood sugar management.
Dosage and Administration
Adult dosage
This medicine may be administered as monotherapy or in combination with metformin in patients with no prior experience of antidiabetic drug therapy. The dose is 50mg once daily in the morning, or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione alone, the recommended dose of this medicine when used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea alone, the recommended dose of this medicine when used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose of this medicine as add-on therapy (third-agent therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this medicine when used in combination is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food. Doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. - Moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under ‘3. General precautions’ in Precautions for use.)
Precautions
This medication should not be used in certain patients. Patients with an allergy to the active ingredient or other components of this medication, those with type 1 diabetes or diabetic ketoacidosis, should not take this medication. Additionally, as it contains lactose, patients with lactose intolerance or related genetic conditions should also avoid taking this medication. This medication includes sodium pyroglutamate, which may cause allergic reactions or asthma attacks in some patients, so patients with asthma should exercise particular caution. While taking this medication, liver function abnormalities may rarely occur, so it is important to have regular liver function tests before starting and while on this medication. If liver enzyme levels persist more than three times the upper limit of normal or symptoms such as jaundice appear, discontinuation of the medication must occur immediately. This medication does not replace insulin therapy and should be used cautiously in patients with severely impaired kidney function. Due to the risk of hypoglycemia, patients taking this medication with other diabetes medications such as sulfonylureas should be vigilant for symptoms of hypoglycemia and adjust the dosage of those medications as necessary. Symptoms such as dizziness may occur, so caution is needed while driving or operating machinery. Furthermore, if severe joint pain or blistering or ulceration of the skin occurs while taking this medication, consult a physician immediately, and if acute pancreatitis symptoms appear, discontinue the medication and notify medical personnel. Pregnant or breastfeeding women should preferably avoid taking this medication, and its safety and effectiveness in children or adolescents under 18 years have not been established, therefore it is not recommended. In case of overdose, there is no specific antidote, so symptoms must be monitored and supportive care should be provided, and this medication is not removed by hemodialysis. Finally, this medication should be kept out of reach of children, and transfer to other containers should be avoided as it may negatively affect the quality of the medication.
Side effects
Hepatitis, abnormal liver function, elevated transaminase levels, angioedema, hypoglycemia, tremor, headache, dizziness, fatigue, nausea, constipation, weakness, weight gain, peripheral edema, gastroesophageal reflux, diarrhea, abdominal distension, chills, decreased blood sugar, hyperhidrosis, nasopharyngitis, upper respiratory tract infection, pancreatitis, urticaria, blistering, exfoliative dermatosis, arthralgia accompanied by severity and disability, cutaneous vasculitis, cholecystitis, acute myocardial infarction, nodal arrhythmia, acute cholecystitis, pneumothorax, cholelithiasis, femoral fracture, peripheral artery occlusive disease, supraventricular tachycardia, congestive heart failure, gastric ulcer, gastric cancer, increased INR, appendicitis, pulmonary edema, vertigo, pruritus, dry mouth, vomiting, insomnia, dyspepsia, renal impairment, lip blisters, drowsiness, chest discomfort, hunger, sensory loss, spinal canal stenosis, abdominal pain, gastroenteritis, gastritis, gastric ulcer, belching, angina, cardiac arrest, renal cyst, lung carcinoma, leg pain, elevated C-reactive protein, myalgia, paresthesia, fever, edema, peripheral edema, elevated creatine phosphokinase, increased C-reactive protein, elevated myoglobin levels
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture, and should be kept at room temperature between 1°C and 30°C. This will help maintain the medication's effectiveness over time.
Appearance and packaging
Appearance
White to light yellow round tablets
Package unit
30 tablets/bottle
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
